A Scientific Advisory Panel (SAP) in June 2009 concluded that a common mode of action existed for pyrethroids, with two subgroups. The purpose of this SAP was to advise the U.S. Environmental Protection Agency on the validity of regulation of pyrethroids as a single class under the Food Quality Protection Act of 1996. Two types of pyrethroid action were first described for clinical signs in the rat and clinical signs/nerve effects in the cockroach. In insects, Type I clinical signs correlate with repetitive firing in nerve axons, especially fine sensory axons. The Na(+) inward current is via a TTX-sensitive voltage-gated sodium channel (VGSC). Type II (α-CN) effects on VGSCs do not include repetitive firing following stimulation in these axons. Instead, Type II effects on VGSCs include prolonged Na(+) tail currents along with depolarization of nerve membrane. Other Type II effects have been measured on VG Ca(2+) and K(+) channels and VG and GABA-activated Cl(-) channels. In conclusion, in vivo pyrethroid effects in mammals should be linked with specific channel effects, allowing the use of specific clinical signs or ion channel effects for pyrethroid risk assessment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/jf103901k | DOI Listing |
Blood Adv
January 2025
Mayo Clinic, Rochester, Minnesota, United States.
In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic review and meta-analysis of 62 studies, encompassing 3,487 patients from the years 1960 to 2022. Our findings reveal that patients with up to 10% clonal plasma cells in their bone marrow (BM), denoted as plasmacytoma +, had a significantly reduced median disease-free survival (DFS) of 15.7 months vs.
View Article and Find Full Text PDFBackground: Assisted partner services (APSs; sometimes called index testing) are now being brought to scale as a high-yield HIV testing strategy in many nations. However, the success of APSs is often hampered by low levels of partner elicitation. The Computer-Assisted Self-Interview (CASI)-Plus study sought to develop and test a mobile health (mHealth) tool to increase the elicitation of sexual and needle-sharing partners among persons with newly diagnosed HIV.
View Article and Find Full Text PDFJ Med Internet Res
January 2025
Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Background: Primary intracranial germ cell tumors (iGCTs) are highly malignant brain tumors that predominantly occur in children and adolescents, with an incidence rate ranking third among primary brain tumors in East Asia (8%-15%). Due to their insidious onset and impact on critical functional areas of the brain, these tumors often result in irreversible abnormalities in growth and development, as well as cognitive and motor impairments in affected children. Therefore, early diagnosis through advanced screening techniques is vital for improving patient outcomes and quality of life.
View Article and Find Full Text PDFJMIR Res Protoc
January 2025
Graduate Program of Psychiatry and Behavioral Sciences, Department of Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
Background: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition emerging in early childhood, characterized by core features such as sociocommunicative deficits and repetitive, rigid behaviors, interests, and activities. In addition to these, disruptive behaviors (DB), including aggression, self-injury, and severe tantrums, are frequently observed in pediatric patients with ASD. The atypical antipsychotics risperidone and aripiprazole, currently the only Food and Drug Administration-approved treatments for severe DB in patients with ASD, often encounter therapeutic failure or intolerance.
View Article and Find Full Text PDFNeurology
February 2025
Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Determining the level of consciousness in patients with brain injury-and more fundamentally, establishing what they can experience-is ethically and clinically impactful. Patient behaviors may unreliably reflect their level of consciousness: a subset of unresponsive patients demonstrate covert consciousness by willfully modulating their brain activity to commands through fMRI or EEG. However, current paradigms for assessing covert consciousness remain fundamentally limited because they are insensitive, rely on imperfect assumptions of functional neuroanatomy, and do not reflect the spectrum of conscious experience.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!